The availability of suzetrigine may represent a critical step in addressing the nation’s pain management crisis. While ...

UMass Lowell Recognized as Top Research Institution with R1 Classification Read More ⁠ ...

What should investors who are experiencing Nasdaq market whiplash do now? I think buying three Nasdaq stocks hand over fist and holding them for decades is a smart move.

Pain is good. Or finding non-opioid ways to manage it is good, if Latigo Biotherapeutics’ $150 million March fundraise is ...

The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

The recent selloff has GreensKeeper excited about the price declines. Click here to read on to learn about our response to ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, ...

The clinical name is suzetrigine. The brand name is Journavx, and it may be the biggest breakthrough in opioid alternatives in...well ever. It is the first new pain medication approved by the FDA in ...

The justices threw out a lower court's decision that the FDA had failed to follow proper legal procedures under a federal law called the Administrative Procedure Act when it rejected the ...